I doubt that the deal value would have been much higher without the overhang given the size of the Asian TTR market. But then, of course, nothing can surprise me here any more and a resolution to the Alnylam-Tekmira troubles may already have been hammered out. A clue may be how Tekmira responds to the news. If there is tonight a we-are-pleased-that-Genzyme-has-partnered-ALN-TTR02-for-which-we-provide-the-delivery-technology-PR, then it's probably nothing to get excited about. But if there is silence, then maybe the real news may come with a slight delay.
Monday, October 22, 2012
Genzyme Taps RNAi Therapeutics for TTR Amyloidosis
I doubt that the deal value would have been much higher without the overhang given the size of the Asian TTR market. But then, of course, nothing can surprise me here any more and a resolution to the Alnylam-Tekmira troubles may already have been hammered out. A clue may be how Tekmira responds to the news. If there is tonight a we-are-pleased-that-Genzyme-has-partnered-ALN-TTR02-for-which-we-provide-the-delivery-technology-PR, then it's probably nothing to get excited about. But if there is silence, then maybe the real news may come with a slight delay.
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.
4 comments:
"Tekmira, this company, as it is customary in biotech sub-licensing, is likely to receive a partial payment out of the $22.5M upfront "
isis got 1.1
tkmr: no idea what is in the agreements. tkmr as a small company probably had not such a good agreement when they signed their tech over to alny.
btw no word from tkmr either with the vsp deal
"You would expect that Genzyme would have at least waited for another month or so before closing the deal (trial date in November)."
Not really. Usually the price and details of an agreement are different when there is less risk. This was probably aready 6+ months in the works.
Look at the VSP deal. I thought it wouldn't happen before the patent/litigation would be done. ALNY just singned it so somebody else would do something with it. And there are probably all kinds of conditions on royalties and payments in the agreement depending on what happens with patents/litigation.
"tkmr as a small company probably had not such a good agreement when they signed their tech over to alny."
I've heard this argument before: yes, TKMR got screwed, but since it's the small company it probably got screwed over legally. 'Signed their tech over to alny'- laughable.
It'll be nice once they can shift more focus on FH. I wonder if the Genzyme deal will have a positive effect on hypercholesterolemia and the treatment for it.
Post a Comment